Literature DB >> 31521671

Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer.

Shawn P E Nishi1, Jie Zhou2, Ikenna Okereke3, Yong-Fang Kuo4, James Goodwin5.   

Abstract

BACKGROUND: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT.
METHODS: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population.
RESULTS: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%).
CONCLUSIONS: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LDCT; NLST; chest imaging; computed tomography; follow up; health-care utilization; imaging; lung cancer screening; procedures

Mesh:

Year:  2019        PMID: 31521671      PMCID: PMC7005377          DOI: 10.1016/j.chest.2019.08.2187

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.

Authors:  Paul F Pinsky; David S Gierada; William Black; Reginald Munden; Hrudaya Nath; Denise Aberle; Ella Kazerooni
Journal:  Ann Intern Med       Date:  2015-04-07       Impact factor: 25.391

3.  Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT.

Authors:  J C M van de Wiel; Y Wang; D M Xu; H J van der Zaag-Loonen; E J van der Jagt; R J van Klaveren; M Oudkerk
Journal:  Eur Radiol       Date:  2007-01-06       Impact factor: 5.315

4.  CT screening for lung cancer: alternative definitions of positive test result based on the national lung screening trial and international early lung cancer action program databases.

Authors:  Rowena Yip; Claudia I Henschke; David F Yankelevitz; James P Smith
Journal:  Radiology       Date:  2014-06-19       Impact factor: 11.105

5.  Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography.

Authors:  Michael J Kucharczyk; Ravi J Menezes; Alexander McGregor; Narinder S Paul; Heidi C Roberts
Journal:  Can Assoc Radiol J       Date:  2010-04-10       Impact factor: 2.248

6.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

7.  Monitoring Lung Cancer Screening Use and Outcomes at Four Cancer Research Network Sites.

Authors:  Michael K Gould; Lori C Sakoda; Debra P Ritzwoller; Michael J Simoff; Christine M Neslund-Dudas; Lawrence H Kushi; Lisa Carter-Harris; Heather Spencer Feigelson; George Minowada; V Paul Doria-Rose
Journal:  Ann Am Thorac Soc       Date:  2017-12

8.  Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial.

Authors:  Xuan V Nguyen; Louise Davies; James D Eastwood; Jenny K Hoang
Journal:  J Am Coll Radiol       Date:  2017-03       Impact factor: 5.532

9.  Baseline characteristics of participants in the randomized national lung screening trial.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; Jonathan D Clapp; Kathy L Clingan; Ilana F Gareen; David A Lynch; Pamela M Marcus; Paul F Pinsky
Journal:  J Natl Cancer Inst       Date:  2010-11-22       Impact factor: 13.506

10.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

View more
  3 in total

1.  The Effects of Perinodular Features on Solid Lung Nodule Classification.

Authors:  José Lucas Leite Calheiros; Lucas Benevides Viana de Amorim; Lucas Lins de Lima; Ailton Felix de Lima Filho; José Raniery Ferreira Júnior; Marcelo Costa de Oliveira
Journal:  J Digit Imaging       Date:  2021-03-31       Impact factor: 4.903

2.  Propensity-score-matching analysis to compare efficacy and safety between 16-gauge and 18-gauge needle in ultrasound-guided biopsy for peripheral pulmonary lesions.

Authors:  Weijun Huang; Jieyi Ye; Yide Qiu; Weiwei Peng; Ninghui Lan; Weizhen Cui; Ting Huang; Yinghui Ou; Yingjia Li
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

3.  Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer: A case-control study.

Authors:  Xiaoping Hu; Wenjun Huang; Feng Wang; Yifei Dai; Xiaocong Hu; Daoyuan Yue; Shaomin Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.